What question did this study set out to answer?

This study aims to gather real-world data on the spectrum, timing, severity, and outcomes of immune-related adverse events in patients receiving immune checkpoint inhibitors.

May 29, 2026Journal of Clinical Oncology

Real-world data on clinical profile of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in oncology.

View Full Paper

Ask AI

Bookmark

This study aims to gather real-world data on the spectrum, timing, severity, and outcomes of immune-related adverse events in patients receiving immune checkpoint inhibitors.
Conducted a retrospective cohort study on adult oncology patients treated with ICIs from Jan 2018 to Dec 2024.
IrAEs categorized by organ system, timing of onset (early, intermediate, late), and severity based on CTCAEv6.0 criteria.
Assessed management strategies, therapy discontinuations, hospitalizations, and survival rates.
Out of 652 patients screened, 169 (26%) experienced irAEs, with thyroid (43%) and skin (28.4%) being the most affected organs.
IrAEs presented at various times: 41.4% before 12 weeks, 44.4% between 12-24 weeks, and 91.3% after 24 weeks.
Grade >2 irAEs increased mortality risk (HR 2.7, 95% CI 1.1-6.5).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective cohort study analyzes immune-related adverse events in oncology patients treated with ICIs, suggesting the need for long-term monitoring.

Cite This Study

Sudha et al. (2026) studied this question.

synapsesocial.com/papers/6a192eb9fab5b468c4417ef7 https://doi.org/10.1200/jco.2026.44.16_suppl.11151

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study analyzes immune-related adverse events in oncology patients treated with ICIs, suggesting the need for long-term monitoring.

Real-world data on clinical profile of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in oncology.

Key Points

Discussion

Implication

Cite This Study

Real-world data on clinical profile of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in oncology.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider